Crystal structures of native and thrombin-complexed heparin cofactor II reveal a multistep allosteric mechanism by Baglin, T. P. et al.
Crystal structures of native and thrombin-complexed
heparin cofactor II reveal a multistep
allosteric mechanism
Trevor P. Baglin†, Robin W. Carrell†, Frank C. Church‡, Charles T. Esmon§, and James A. Huntington†¶
†Department of Haematology, Cambridge Institute for Medical Research, Wellcome TrustMRC Building, Hills Road, Cambridge CB2 2XY, United Kingdom;
‡Department of Pathology and Laboratory Medicine, University of North Carolina, Chapel Hill, NC 27599-7035; and §Cardiovascular Biology Research
Program, Oklahoma Medical Research Foundation, Howard Hughes Medical Institute, and Department of Pathology and Biochemistry and
Molecular Cell Biology, University of Oklahoma Health Science Center, Oklahoma City, OK 73104
Edited by Earl W. Davie, University of Washington, Seattle, WA, and approved June 24, 2002 (received for review April 17, 2002)
The serine proteases sequentially activated to form a fibrin clot are
inhibited primarily by members of the serpin family, which use a
unique -sheet expansion mechanism to trap and destroy their
targets. Since the discovery that serpins were a family of serine
protease inhibitors there has been controversy as to the role of
conformational change in their mechanism. It now is clear that
protease inhibition depends entirely on rapid serpin -sheet ex-
pansion after proteolytic attack. The regulatory advantage af-
forded by the conformational mobility of serpins is demonstrated
here by the structures of native and S195A thrombin-complexed
heparin cofactor II (HCII). HCII inhibits thrombin, the final protease
of the coagulation cascade, in a glycosaminoglycan-dependent
manner that involves the release of a sequestered hirudin-like
N-terminal tail for interaction with thrombin. The native structure
of HCII resembles that of native antithrombin and suggests an
alternative mechanism of allosteric activation, whereas the struc-
ture of the S195A thrombin–HCII complex defines the molecular
basis of allostery. Together, these structures reveal a multistep
allosteric mechanism that relies on sequential contraction and
expansion of the central -sheet of HCII.
The predominant protease inhibitors of the higher organisms,the serpins (1, 2), have evolved a complex mechanism that
was revealed recently by the crystallographic structure of a
serpin–protease complex (3). This dramatic mechanism amounts
to a race between proteolysis and the incorporation of the
serpin-reactive center loop into its main -sheet (-sheet A). The
dependence of the serpin inhibitory mechanism on -sheet
expansion renders serpins highly susceptible to both loss-of-
function and gain-of-function diseases but additionally allows for
a range of mechanisms for the modulation of serpin activity.
Thus, serpins typically are found controlling tightly regulated
physiological pathways such as blood coagulation. Antithrombin
(AT) and heparin cofactor II (HCII) have independently (4, 5)
evolved mechanisms by which they circulate in an inert state until
activated by binding to cell surface glycosaminoglycans (GAGs).
AT and HCII thus are allosterically activated toward factor Xa
and thrombin, respectively, the final two proteases in the blood
coagulation cascade.
The structure and mechanism of activation of AT has been
well characterized. Its fold is similar to that of the rest of the
serpin family with the single and important exception that the
reactive center loop is constrained through partial incorporation
into -sheet A (refs. 6 and 7; Fig. 1a). The native conformation
of AT thus renders it incapable of forming a productive recog-
nition complex (Michaelis complex) with factor Xa, and only as
the result the conformational changes brought about through the
interaction with a specific heparin pentasaccharide sequence
does AT become an efficient inhibitor of factor Xa. Pentasac-
charide binding results in secondary structural changes in the
heparin binding region and the expulsion of the reactive center
loop (8) such that activated AT resembles all the other known
native inhibitory serpins with a fully exposed reactive center loop
and a five-stranded -sheet A (Fig. 1a).
The reactive center-loop sequence of HCII implies specificity
for chymotrypsin, with a leucine in the critical P1 position (where
the scissile bond is denoted P1–P1; ref. 9), yet it is a specific
inhibitor of thrombin, which normally requires a P1 arginine.
The specificity of HCII for thrombin is conferred by a highly
acidic hirudin-like N-terminal tail, which becomes available after
GAG binding for interaction with the anion-binding exosite I of
thrombin (10–14). A mechanism for HCII activation has been
proposed (11, 15) whereby the N-terminal tail is sequestered in
the native structure through an interaction with the highly basic
heparin binding region, and activation is brought about through
the competitive displacement of the acidic tail of HCII by
heparin or similar anionic GAGs. Here we describe, in turn, the
crystallographic structures of native and S195A thrombin-
complexed HCII. The native structure displays unexpected
homology to AT, which provides a previously uncharacterized
mechanism for sequestration and release of the acidic tail, and
the Michaelis complex between HCII and thrombin defines the
molecular basis of activation. Together, these structures reveal a
multistep mechanism that depends on the sequential contraction
and expansion of -sheet A and demonstrate the degree to which
the complicated serpin mechanism of protease inhibition has
been exploited by evolution to effect regulatory control.
Methods
Native HCII. HCII was purified as described (16). Crystals were
obtained from Hampton Crystal Screen Cryo 6 (Hampton
Research, Riverside, CA) and were generally very thin plates
that diffracted poorly. Crystals were shown to contain intact
HCII by SDSPAGE, although some degradation, presumably
N-terminal cleavage, was observed in older crystals. A data set
was collected on a single frozen crystal at the SRS Daresbury
Station 14.1 (Cheshire, U.K.) on an ADSC image plate. The
crystal diffraction was nonisotropic, and significant decay was
observed during data collection. The data were processed using
MOSFLM, SCALA, and TRUNCATE (17) and were of reasonable
quality to a resolution limit of 2.35 Å (Table 1). The structure of
native HCII was solved by molecular replacement (MolRep; ref.
18) using native plasminogen activator inhibitor-1 (PDB ID code
1DVN), native AT (PDB ID code 1EO5), latent AT (PDB ID
code 1EO5), and pentasaccharide-activated AT (PDB ID code
1AZX) as search models. Comparison of the relative scores for
the molecular replacement solutions clearly indicated that the
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best solution was for native AT and that two monomers occupied
the asymmetric unit. A homology model of HCII was generated
on the native AT template by using SWISSMODEL (19), which then
was subjected to rigid-body refinement and coordinate refine-
ment with simulated annealing by using CNS (20). The Rfree set
was chosen randomly from a subset of reflections unrelated by
noncrystallographic symmetry. Iterative rounds of rebuilding in
XTALVIEW (21) and refinement with CNS resulted in an Rfactor and
Rfree of 20.8 and 24.7, respectively (Table 1). Because the twofold
noncrystallographic symmetry axis was nearly crystallographic,
averaged, solvent-f lattened maps were calculated with 5,284
unobserved reflections regenerated using the program DM (22).
HCII–S195A Thrombin Complex. S195A thrombin was produced as
described (23). The 1:1 complex of S195A thrombin and HCII,
concentrated to 8–10 mgml, was crystallized in 0.06M NH4Cl
and 6% polyethylene glycol 3350. The crystals were large and
hexagonal (400  400  300 m) but diffracted poorly and
decayed rapidly when exposed to X-rays at room temperature.
Improved diffraction was achieved through systematic dehydra-
tion by the sequential rapid stepping-up of 2-methyl-2,4-
pentanediol (MPD) concentration from 0 to 20% in 2% incre-
ments. The crystal was flash frozen and data were collected and
processed as above. The structure of the complex was solved by
molecular replacement using the program MOLREP with our
structure of S195A thrombin (PDB ID code 1JOU) and with the
N-terminal half of native HCII (residues 100–265) as search
models. The C-terminal half of HCII (residues 282–480) was
subsequently positioned with the solutions for thrombin and the
N-terminal fraction fixed. Molecular replacement attempts with
native HCII were unsuccessful even with the thrombin solution
fixed using both MOLREP and AMORE (24). The final refined
model was obtained as described above. Solvent-f lattened maps
were calculated by using DM because of the unusually high
solvent content (72%). Processing and refinement statistics are
given in Table 1. Figures were made by using MOLSCRIPT (25),
BOBSCRIPT (26), RASTER3D (27), and GRASP (28).
Results and Discussion
Overall Structure of Native HCII. The overall structure of native
HCII is nearly identical to that of native AT, with a six-stranded
-sheet A due to the partial incorporation of the reactive center
loop (Fig. 1). Superposition of HCII and AT results in an rms
deviation of 1.8 Å for 352 equivalent C atoms despite the rather
low sequence identity of 26.8%. It is likely that AT and HCII
have coincidentally adopted the same native conformation for
the same purpose, that of sequestering the reactive center loop
so as to render the circulating form nonreactive toward target
and nontarget proteases, and that GAG binding will result in
expulsion of the reactive center loop of HCII, as with AT (Fig.
1a). One of the major surprises in finding native HCII in this
conformation is that the P1 leucine would already render a
normal loop-expelled, five-stranded native form inactive toward
thrombin. This fact has been demonstrated by studies that show
Fig. 1. The AT-like structure of native HCII. (a) The native structure of AT is different from all other know serpins with the partial incorporation of the reactive
center loop (yellow) into -sheet A (red), resulting in an unfavorable orientation of the reactive center arginine side chain (red, space-filling). Binding of heparin
(ball-and-stick) to helix D (cyan) results in the expulsion of the reactive center loop from -sheet A and its freeing for the formation of a productive Michaelis
complex. (b) The structure of native HCII resembles that of native AT, with its reactive center loop partially inserted into -sheet A. (c) Stereo depiction of the
electron density for the entire reactive center loop contoured at 1. (d) The high degree of conservation of heparin binding residues on helix D (cyan) and helix
A (green) with AT indicates a similar mode of binding and suggests similar conformational changes in response to binding. (e) A stereo representation of the
crystallographic dimer of HCII formed by the antiparallel -sheet interaction between strands 1C (orange) of each monomer. This contact is the probable cause
of the displacement of the acidic N-terminal tail (magenta). The bottom monomer is molecule A.
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that reactivity toward thrombin requires an intact N terminus
even in the presence of GAG (10). In AT, expulsion of the
reactive center loop after heparin binding also has the effect of
increasing the affinity for heparin by 1,000-fold and globally
altering its surface properties. The AT-like native conformation
of HCII thus provides the basis for a hypothesis for the mech-
anism of its GAG activation, where the acidic N terminus is
released because of the global conformational changes associ-
ated with GAG-induced expulsion of the partially inserted
reactive center loop.
The Heparin Binding Site. The heparin-binding residues of HCII
were identified initially by sequence alignment with AT and have
since been confirmed through the study of variants to be Lys-173,
Arg-184, Lys-185, Arg-189, Arg-192, and Arg-193 on or near
helix D (15). Fig. 1d compares the heparin binding sites of AT
and HCII, with key residues indicated. The critical residues
involved in the tight binding of the heparin pentasaccharide by
AT have been demonstrated by both structural and biochemical
studies to include Lys-114, Lys-125, and Arg-129, whereas Arg-
132, Lys-133, and Lys-136 contribute to the binding of longer
heparin chains (8, 29–33). The conservation in HCII of the key
residues involved in the interaction of the pentasaccharide with
AT supports a similar mechanism of GAG binding by HCII.
Further evidence for a common binding mechanism comes from
the conservation of other AT residues known to interact with
heparin such as Arg-46 and Arg-47 on helix A (34), which
correspond to Lys-101 and Arg-103 in HCII. The structure of the
heparin binding region of native HCII displays an inherent
flexibility in loops containing basic residues critical for GAG
binding and suggests a structural response to GAG binding
similar to that observed for AT.
The Acidic Tail. Although allostery is implied by analogy to AT, the
position for the majority of the acidic tail is undefined in
the structure of native HCII. Of the 160 amino acids in the
N-terminal tails of the two molecules comprising the crystallo-
graphic asymmetric unit (Fig. 1e), only 11 can be unequivocally
placed in density (Leu-61–Asp-71). It was not possible to assign
the observed portion of the acidic tail to a particular molecule
in the asymmetric unit based on connectivity of electron density,
but it most likely belongs to molecule A because of limitations
of available threading pathways through the crystal.
The fact that the acidic tail is not ordered in the crystallographic
structure of HCII indicates that it is flexible within the crystal. It is
unlikely that the acidic tail is flexible in solution, because it is not
proteolytically susceptible in the native state (35). Thus, the native
position of the acidic tail has been perturbed by crystal contacts.
The proposal that the tail interacts with the heparin binding site
located on helix D is not supported by this structure, because there
are no crystal contacts on helix D, and no unassigned electron
density is found in this region. The most stable interaction within
the crystal is that between the two molecules that makeup the
asymmetric unit (Fig. 1e). This antiparallel -sheet interaction
between strands 1 of sheet C (orange) results in a continuous sheet
C from molecule A to molecule B. The stability of such an interface
has been demonstrated by the observation of similar interactions in
crystals and in solution for AT (7, 36) and plasminogen activator
inhibitor-1 (37, 38). The interface between the two monomers also
corresponds to the position of the fragment of the acidic tail
observed in the structure. It thus is likely that the dimerization of
monomers to form the asymmetric unit is required for crystalliza-
tion and results in an unfavorable apposition of the two acidic tails,
which would place a portion of the acidic tail in native HCII in
contact with sheet C.
Overall Structure of the HCII–S195A Thrombin Michaelis Complex. The
prediction from the native structure alone is that the activated form
of HCII will have an expelled reactive center loop and thus a
five-stranded -sheet A, as occurs in AT activation (Fig. 1a), which
was verified by the solution of the crystal structure of HCII in
complex with the enzymatically inert S195A variant of human
thrombin (Fig. 2a). Thrombin is oriented at the top of the serpin,
in the classic view, and slightly behind and to the left with the
heparin binding site of thrombin (exosite II) aligned with the helix
D of HCII to allow heparin bridging. Although this complex
represents a Michaelis complex between a serpin and a protease, it
cannot be generalized to all serpin–protease Michaelis complexes
Table 1. Crystals, data processing, refinement, and models
Crystals Native HCII HCII–S195A-thrombin complex
Space group P21 P61
Cell dimensions, Å a  74.7, b  80.0, c  92.2,   102.0° a, b  152.3, c  126.81
Solvent content, % 46 72
Data-processing statistics
Wavelength, Å 1.488 1.488
Resolution, Å 25.1–2.35 29.4–2.2
Total reflections 112,978 475,985
Unique reflections 39,178 77,117
I(I) 4.0 6.5
I(I) 11.7 14.8




No. of proteinwater atoms 6,376297 5,933208
Average B factor, Å2 37.7 55.0
Refinement statistics
Reflections in workingfree set 38,162994 76,094983
RfactorRfree 20.824.7 20.521.1
rms deviation of bonds, Åangles, °, from ideality 0.0061.3 0.0061.4
Ramachandran plot; residues in
Most favored region, % 90.8 86.5
Additionally allowed region, % 9.1 12.1
Generously allowed region, % 0 1.1
Disallowed region, % 0.1 0.3








because of the intimacy of the interface. NMR studies on the
antitrypsin–anhydrotrypsin complex (39) and a recently published
structure of the Manduca Sexta serpin–S195A trypsin complex (40)
demonstrate a flexible Michaelis complex where the serpin and the
protease rotate as independent bodies. In these cases, the specificity
is determined wholly by the reactive center loop sequence and in
particular the P1 residue. Thus, to render the Michaelis complexes
between antitrypsin or the Manduca Sexta serpin and trypsin stable
enough for NMR and crystallography, the P1 residue was changed
from Met3 Arg and from Leu3 Lys, respectively. The ability of
HCII to form a productive Michaelis complex with thrombin
depends on exosite interactions and thus can accommodate a
leucine at the P1 position. In the HCII–S195A thrombin complex,
thrombin is effectively docked on the plane of sheet C and makes
simultaneous contacts with the acidic tail and the reactive center
loop, resulting in a complex that, in solution, would rotate as a rigid
body.
It is clear from this structure why the reactive center loop
needs to be released from the constraints of partial -sheet
incorporation to form the Michaelis complex with thrombin; in
striking contrast to the structure of the Manduca Sexta serpin–
trypsin Michaelis complex (40), the reactive center loop has been
stretched to the maximal extent to simultaneously make subsite
contacts with thrombin within the reactive center loop and
elsewhere in the molecule. The reactive center loop forms a tight
turn in the active site cleft of thrombin, and the hirudin domain,
sandwiched between HCII and thrombin, participates in exten-
sive hydrophobic and two electrostatic interactions with exosite
I of thrombin. The position of the hirudin tail is well defined in
the structure of the complex, with uninterrupted density from
residue 54 to 83 (Fig. 2b) and from 94 to the N terminus of helix
A. The tail interacts with thrombin from residue 56 to 72 and
then is entirely free from noncrystallographic interactions until
residue 94. The striking flexibility of the intervening portion of
the tail is evident in the stereo representation of the complex
(Fig. 2a) and is in keeping with the degree of mobility required
to allow the extraordinary displacement of thrombin that is
central to the serpin inhibitory mechanism.
The Interface. The Michaelis complex between HCII and throm-
bin differs from previously characterized serpin–protease
Michaelis complexes in the extent of subsite interactions outside
the reactive center loop. It is the strength of these exosite
interactions that accounts for the high rate of thrombin inhibi-
tion by GAG-activated HCII. The interaction interface can be
divided into three regions of HCII that make important contacts
with thrombin: (i) the reactive center loop, (ii) sheet C and
elsewhere, and (iii) the acidic tail.
The Reactive Center Loop. The reactive center loop of native HCII
is constrained by its partial incorporation into -sheet A, which
was a surprise finding that is explained nicely by the structure of
HCII–S195A thrombin complex; in order for thrombin to simul-
taneously bind to the reactive center and form interactions
elsewhere, the reactive center loop must be expelled and indeed
stretched to the fullest extent possible. Thus, loop expulsion after
Fig. 2. Crystallographic structure of the HCII–thrombin Michaelis complex. (a) A stereo representation of the Michaelis complex between S195A thrombin (cyan)
and HCII (colored as described for Fig. 1), with the -loop in front and the 60-insertion loop behind the reactive center loop. (b) Stereo representation of the
electron density covering the portion of the acidic tail (yellow) that interacts with thrombin (magenta), contoured at 1. (c) The subsite interactions between
the reactive center residues of HCII (rods) and the active site cleft of thrombin (surface representation) are extensive and complementary in both electrostatic
(Left, negative potential is red, and positive is blue) and hydrophobic (Right, green for hydrophobic side chains) properties. (d) The interaction between exosite
I of thrombin (surface representation as described for c) and the hirudin-like N-terminal tail of HCII (rods, the side chains of residues not interacting with thrombin
were removed for clarity) is primarily hydrophobic. The only ionic interactions are between Asp-70 and Asp-72 of HCII and L110H of thrombin. Sulfated tyrosines,
60 and 73, make no contacts with thrombin and are not shown.
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GAG binding is a necessary part of the activation mechanism.
The interactions with thrombin involve residues P4–P5 (Phe-
441–Arg-449), which form a tight loop within the active site. The
interactions are illustrated by surface representations of the
active site of thrombin colored according to electrostatic and
hydrophobic properties in Fig. 2c.
Sheet C and Elsewhere. Thrombin differs most significantly from
other serine proteases in the extensions at residues 60 and 147,
known as the 60-insertion and -loops (41), which restrict access of
substrates to the active site. The 60-insertion loop makes several
contacts within the reactive center loop, but it also makes contacts
elsewhere on the body of HCII. A critical contact is the salt bridge
between Asp60E of thrombin and Arg-369 of HCII. The -loop
makes no favorable contacts within the reactive center loop of HCII
but has extensive interactions with residues on or adjacent to
-sheet C. Trp147A is buried in a hydrophobic pocket formed by
Met-288, Gln-308, His-290 of HCII, and the backbone of the -loop
itself. Asn147D forms hydrogen bonds with main chain atoms of
Glu-287, Thr-289, and Val-286 of HCII. These interactions, al-
though not expected to contribute greatly to the binding energy for
the HCII–thrombin Michaelis complex, illustrate the strategy of
HCII in accommodating these bulky thrombin loops, which is in
contrast to AT, which simply possesses a longer reactive center loop.
The Acidic Tail. The acidic tail of HCII contains two so-called hirudin
domains, 56EDDDY*LD62 and 69EDDDY*ID75, each of which
contains several acidic amino acids and a sulfated tyrosine. The
interface between the acidic tail and thrombin in the structure of
the HCII–S195A thrombin complex is striking in that there are only
two ionic interactions (Asp-70 and Asp-72 with Leu110H). Much
like the hirudin–thrombin complex (PDB ID code 1FPH; ref. 42),
the majority of the contacts are hydrophobic (Fig. 2d). The anion-
binding exosite I contains a very hydrophobic face made up of
Phe-34, Leu-65, Arg-67, Tyr-76, Ile-82, and Met-84. In the HCII–
thrombin Michaelis complex, this hydrophobic patch is well covered
by an amphipathic helix, which lies between the two highly acidic
hirudin domains, and includes residues Leu-61, Leu-63, Ile-66, and
Phe-67. The analogous region on hirudin does not form a helix but
contains a similar complement of hydrophobic residues. The N- to
C-terminal orientation of the acidic tail on exosite I also is the same
as for hirudin.
The N-terminal hirudin domain is effectively sandwiched in
between HCII and thrombin, and its only ionic interaction is
intramolecular (Asp-58–Arg-295). The sulfated tyrosine (Sty60)
is also making intramolecular contacts with the main chain
amide hydrogen of Met-344, which is the only contact made for
either of the two sulfated tyrosines in HCII. The sulfated
tyrosines thus may be more important for intramolecular inter-
actions that sequester the acidic tail in the native state than for
the stabilization of the HCII–thrombin complex. All other
interactions are main chain or side chain hydrogen bonds
involving Glu-56, Asp-57, Asp-59, and Leu-61.
Allosteric Activation of HCII. How the acidic tail is freed by heparin-
like GAGs for the formation of the initial complex with thrombin
depends on where the tail is in native HCII. Although the native
structure does not provide an unequivocal position for the tail, it
does provide clues as to where it may reside. First, it is not where
it appears in the structure of the native HCII dimer (Fig. 1e),
because the observed portion of the tail interacts only weakly with
the body of HCII. Second, it is not bound to the GAG-binding
region (helix D) as predicted (10), because this part of the molecule
is free of crystal contacts in the native crystal, and no electron
density is observed. Third, the identical orientation of the N-
terminal loop of helix A (residues 94–101) implies an initial position
Fig. 3. The sequential mechanism of GAG-mediated thrombin inhibition by HCII (as described in Results and Discussion). For a video of this mechanism, see
Movie 2.








very similar to that found in the structure of the HCII–S195A
thrombin complex. Thus, a model for the position of the tail in
native HCII was created based on the above considerations and the
assumption that s1C dimerization disrupts the position of the tail in
the crystal of native HCII. Additionally, a recent study has dem-
onstrated a re-formable disulfide bond for the P52C, F195C HCII
variant, which imposes a strict distance constraint. A good model
for the position of the acidic tail in native HCII would require both
charge complementarity and the burying of the hydrophobic face of
the amphipathic helix against a hydrophobic patch on the body of
HCII. These factors are nicely but not uniquely satisfied by the
model shown in Fig. 3 (model 1). This model suggests that the acidic
tail in native HCII would interfere with thrombin docking and is
consistent with the higher basal rate of thrombin inhibition for the
tail-deleted HCII variant (43). An attractive alternative to the
positioning of the tail illustrated in the Fig. 3 would be to place it
in contact with the reactive center loop itself. Such a position would
explain why the acidic tail is susceptible to proteolysis after cleavage
of the reactive center loop (44). In either case, the extended nature
of the predicted interactions between the acidic tail and the body
of HCII is consistent with an allosteric mechanism for its release.
The conformational changes associated with the expulsion of the
reactive center loop of HCII are manifested in gross changes in
surface shape and properties of HCII. How these conformational
changes could release the acidic tail is illustrated by the comparison
of the surface electrostatic and hydrophobic contours of the region
adjacent to the GAG-binding site and the thrombin-docking region.
A video depiction that flips between the two conformations illus-
trates the magnitude of these changes in shape and properties
(Movie 1, which is published as supporting information on the
PNAS web site, www.pnas.org).
The HCII Mechanism. The structures presented here, combined with
those of AT and the final serpin–protease complex, reveal a
multistep allosteric mechanism for HCII (Fig. 3). A video, based on
these frames, is shown in Movie 2, which is published as supporting
information on the PNAS web site. Briefly, the binding of HCII to
GAG at the cell surface initiates conformational changes including
the expulsion of the reactive center loop, closure of -sheet A, and
the consequent release of the acidic tail (Fig. 3, models 1 and 2).
Through an induced-fit mechanism analogous to that of AT, the
five-stranded, activated conformation of HCII binds its specific
GAG with a greater affinity. The hirudin-like tail of HCII is now
free to recruit and tether thrombin (model 3). Similarly, the reactive
center loop is free to make subsite contacts within the active site
cleft of thrombin (model 4), followed by a tilting movement that
allows the thrombin and the bound hirudin domain to form intimate
contacts with the body of HCII (model 5). The consequent stability
of the Michaelis complex allows for progression into the proteolytic
cycle. At the acyl-enzyme intermediate step, HCII rapidly incor-
porates its reactive center loop into -sheet A, and the tethered
thrombin, still bound to the hirudin-like tail, is translocated to the
opposite pole of HCII (models 6 and 7). Steric clashes induced by
the formation of the final complex disrupt the entirety of exosite I
(45, 46), effecting the re-release of the acidic tail (model 8), and
conformational changes associated with full incorporation of the
reactive center loop prevent the re-binding of the acidic tail to the
body of HCII. The freed tail then can be cleaved (35) by resident
proteases releasing the peptide corresponding to residues 49–60 to
stimulate leukocyte chemotaxis (47–49). Finally, expansion of
-sheet A results in a reduction in affinity for GAG (44), and thus
the HCII–thrombin complex is released from the cell surface for
catabolic destruction (50, 51), enabling the GAG to be recycled for
further catalysis.
The structures presented here illustrate the extent of regula-
tory control afforded by the serpin inhibitory mechanism and go
a long way in explaining why serpins control the critical proteo-
lytic pathways in the higher organisms. The conformational
changes associated with the expansion and contraction of the
central -sheet A define all aspects of HCII activity from
cofactor binding and thrombin recognition to protease inhibition
and cell signaling.
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